Synairgen raises £80m after Covid-19 treatment shows progress

Aidan Gregory

October 15, 2020 08:45 am

Synairgen_plc_PA_575_375 — 26 February 2021, Saxony, Leipzig: In front of a patient's room in the isolation ward at the Clinic for Infectiology/Tropical Medicine, Nephrology and Rheumatology of the St. Georg Hospital in Leipzig, a nurse who wears a mask and goggles puts on protective gloves. With 44 beds, the Clinic for Infectiology is one of the largest facilities of its kind in Germany and is the only competence and treatment centre in Central Germany that is also responsible for the coordination and control of appropriate measures in the event of a suspected dangerous infection. The St. George Clinic and the University want to Photo: Waltraud Grubitzsch/dpa-zentralbild/ZB | Waltraud Grubitzsch/DPA/PA Images

Synairgen, the UK biopharmaceuticals company, has raised £80m from investors to fund the next stage of clinical trials for a treatment designed to alleviate the respiratory symptoms of Covid-19.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request demo or Login

✔ 4,000 annual insights
✔ 700+ notes and long-form analyses
✔ 4 capital markets databases
✔ Daily newsletters across markets and asset classes
✔ 2 weekly podcasts

Topics

Health and Biotech Equity ABBs-Block Trades UK Europe EMEA SRI

AG

Aidan Gregory